George J. Bosl
Memorial Sloan Kettering Cancer Center
276 Papers
3.6K Citations
George J. Bosl is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Germ cell tumors & Retroperitoneal lymph node dissection. The author has an hindex of 67, co-authored 271 publications. Previous affiliations of George J. Bosl include University of Chicago & Memorial Hospital of South Bend.
Chat about Author
Papers
VP-16-213 and cisplatin in the treatment of patients with refractory germ cell tumors.
George J. Bosl,Alan Yagoda,Willet F. Whitmore,Pramod C. Sogani,Harry W. Herr,Davor Vugrin,Mary E. Dukeman,Robert B. Golbey +7 more
TL;DR: VP-16–213 plus cisplatin may be an effective salvage regimen for patients relapsing after a complete remission, but is probably ineffective if the patient has not achieved a prior complete remission.
30
Two-drug therapy in patients with metastatic germ cell tumors.
TL;DR: Etoposide and cisplatin therapy at these doses and schedule results in durable CR without late relapse, and seventy‐one patients remain disease‐free with a median follow‐up time of 63 months.
30
Management of unresectable malignant tumors at the skull base using concomitant chemotherapy and radiotherapy with accelerated fractionation.
Louis B. Harrison,David G. Pfister,Dennis H. Kraus,John G. Armstrong,Michael J. Zelefsky,Jill Wiseberg,George J. Bosl,Elliot W. Strong,Jatin P. Shah +8 more
TL;DR: Treatment of this group of patients with unresectable malignant tumors at the skull base with aggressive chemotherapy and radiation therapy produced excellent local control in the early experience, but longer follow-up is needed.
29
Hormone-secreting metastatic interstitial cell tumor of the testis.
TL;DR: A patient is described with a hormone-secreting interstitial cell tumor, manifesting metastasis 7 years after removal of a reportedly benign primary tumor, which was followed by computerized tomography and serum hormone assays.
28
Cisplatin, fluorouracil, and leucovorin : increased toxicity without improved response in squamous cell head and neck cancer
David G. Pfister,Dean F. Bajorin,Robert J. Motzer,Howard I. Scher,Carl Louison,Louis B. Harrison,Jatin P. Shah,Elliot W. Strong,George J. Bosl +8 more
TL;DR: While PFL is active in patients with SCHN cancer, its use can be associated with significant toxic effects and it is recommended not to recommend the use of PFL for the treatment of patients withSchN cancer outside the context of a clinical trial until there is further critical assessment of its activity and toxicity.
28